◎ Sugi Atlas

Atlas / Disease / Conduct disorder

Conduct disorder

disease
On this page

Summary

Conduct disorder (MONDO:0005352) is a disease with 45 cohort genes (71 GWAS associations across 10 studies) and 82 clinical trials. Top therapeutic interventions include methylphenidate, aripiprazole, and brexpiprazole.

At a glance

  • Cohort genes: 45
  • GWAS associations: 71
  • Clinical trials: 82

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameconduct disorder
Mondo IDMONDO:0005352
EFOEFO:0004216
MeSHD019955
DOIDDOID:12995
NCITC89329
SNOMED CT430909002
UMLSC0149654
MedGen56196
Is cancer (heuristic)no

Data availability: 71 GWAS associations (10 studies).

Disease family

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › mental disorder › developmental disorder of mental health › specific developmental disorder › conduct disorder

Related subtypes (9): fetal alcohol spectrum disorder, oppositional defiant disorder, fetal nicotine spectrum disorder, communication disorder, stereotypic movement disorder, tic disorder, learning disability, developmental coordination disorder, attention deficit-hyperactivity disorder

Genetics & variants

GWAS landscape

71 GWAS associations across 10 studies. Top hits map to 31 distinct genes (as reported by GWAS).

Top associations by p-value

rsIDp-valueGeneRisk alleleOdds ratio
rs2019010882e-11TNFRSF18?
rs168918673e-09C1QTNF7, C1QTNF7-AS1G0.15
rs79508111e-08EEF1A1P49 - SNRPGP16A0.16
rs118389181e-08LINC00331C0.28
rs18610466e-08C1QTNF7, C1QTNF7-AS1A1.65
rs168311284e-07FAM201B - RNU6-175PG1.45
rs104926641e-06NALF1 - LIG4C
rs133988481e-06RNU6-1312P - CRLF3P3G0.17
rs77621601e-06PDE10AC0.07
rs131887712e-06RN7SL802P - OR7H2PA4.24
rs108312842e-06ST13P11 - CWC15G
rs28263402e-06RPS3AP1 - LINC00320T
rs107766122e-06ARHGAP22T1.33
rs17898913e-06ADH1B - ADH1CA1.47
rs65007443e-06RBFOX1C0.91
rs21225543e-06RPLP0P9 - LINC01947A0.1
rs81791163e-06SELPLGA0.23
rs21848983e-06EMX2 - LINC02674A1.33
rs7011574e-06PGBD5 - LINC01737C
rs45332514e-06Metazoa_SRP - FAM149B1P1T
rs72970184e-06PAWRA
rs67333794e-06LINC01320G
rs12565314e-06PTBP1PG0.09
rs15500574e-06RNF150C1.39
rs7195935e-06HNRNPA1P57 - LDHAP3T2.05
rs19510825e-06NOVA1-DT, LINC02294T
rs15574885e-06KIRREL3T
rs9318125e-06Metazoa_SRP - YWHAZC
rs102296035e-06HRAT17C
rs99901746e-06SLC6A1T2.52

Top studies (by case count)

StudyLead authorYearCasesControlsTitle
GCST90481827Verma A20245,310442,073Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST012098Demontis D20213,80231,305Risk variants and polygenic architecture of disruptive behavior disorders in the context of attention-deficit/hyperactivity disorder.
GCST90481826Verma A20242,460117,772Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST012097Demontis D20211,95913,539Risk variants and polygenic architecture of disruptive behavior disorders in the context of attention-deficit/hyperactivity disorder.
GCST90481825Verma A202492558,216Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90651241Liu TY2025135231,742Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.
GCST000713Dick DM201000Genome-wide association study of conduct disorder symptomatology.
GCST000714Dick DM201000Genome-wide association study of conduct disorder symptomatology.
GCST000245Sonuga-Barke EJ200800Does parental expressed emotion moderate genetic effects in ADHD? An exploration using a genome wide association scan.
GCST000253Anney RJ200800Conduct disorder and ADHD: evaluation of conduct problems as a categorical and quantitative trait in the international multicentre ADHD genetics study.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

TierVariants
Tier 1: coding0
Tier 2: splice/UTR3
Tier 3: regulatory0
Tier 4: intronic/intergenic47

MAF distribution

BucketVariants
common (>=0.05)47
low_freq (0.01-0.05)2
rare (<0.01)0
unknown1

Functional consequences

ConsequenceCount
intron_variant29
intergenic_variant17
3_prime_UTR_variant2
non_coding_transcript_exon_variant1
5_prime_UTR_variant1

Top variants

rsIDChrPosAllelesMAFConsequenceGenep-valueTier
rs20190108811203829G>A,C3_prime_UTR_variantTNFRSF182e-11Tier 2: splice/UTR
rs16891867415395740A>G0.097intron_variantC1QTNF7, C1QTNF7-AS13e-09Tier 4: intronic/intergenic
rs79508111192917836C>A,T0.071intron_variantEEF1A1P49 - SNRPGP161e-08Tier 4: intronic/intergenic
rs118389181378836439T>C0.022intron_variantLINC003311e-08Tier 4: intronic/intergenic
rs1861046415396282G>A,C0.095intron_variantC1QTNF7, C1QTNF7-AS16e-08Tier 4: intronic/intergenic
rs168311282132386819A>G0.189intergenic_variantFAM201B - RNU6-175P4e-07Tier 4: intronic/intergenic
rs1049266413108163877C>A,T0.16intergenic_variantNALF1 - LIG41e-06Tier 4: intronic/intergenic
rs13398848284018044A>G0.181intergenic_variantRNU6-1312P - CRLF3P31e-06Tier 4: intronic/intergenic
rs77621606165601943T>C0.365intron_variantPDE10A1e-06Tier 4: intronic/intergenic
rs131887715101612841C>A,G0.17intergenic_variantRN7SL802P - OR7H2P2e-06Tier 4: intronic/intergenic
rs108312841194934799G>A,C,T0.13intergenic_variantST13P11 - CWC152e-06Tier 4: intronic/intergenic
rs28263402120512990A>T0.17intergenic_variantRPS3AP1 - LINC003202e-06Tier 4: intronic/intergenic
rs107766121048527518C>G,T0.481intron_variantARHGAP222e-06Tier 4: intronic/intergenic
rs1789891499329262C>A,G0.14intergenic_variantADH1B - ADH1C3e-06Tier 4: intronic/intergenic
rs6500744166063660C>T0.47intron_variantRBFOX13e-06Tier 4: intronic/intergenic
rs21225545166530081T>A,C,G0.162intergenic_variantRPLP0P9 - LINC019473e-06Tier 4: intronic/intergenic
rs817911612108631651C>A,G,T0.021intron_variantSELPLG3e-06Tier 4: intronic/intergenic
rs218489810117658593G>A0.327intron_variantEMX2 - LINC026743e-06Tier 4: intronic/intergenic
rs7011571230539080T>A,C0.45intron_variantPGBD5 - LINC017374e-06Tier 4: intronic/intergenic
rs45332511596719197T>A,G0.15intron_variantMetazoa_SRP - FAM149B1P14e-06Tier 4: intronic/intergenic
rs72970181279668450A>C,G,T0.19intron_variantPAWR4e-06Tier 4: intronic/intergenic
rs6733379234255008G>A,C,T0.28intron_variantLINC013204e-06Tier 4: intronic/intergenic
rs12565311465281041A>G0.234non_coding_transcript_exon_variantPTBP1P4e-06Tier 4: intronic/intergenic
rs15500574141196270A>C,G,T0.243intergenic_variantRNF1504e-06Tier 4: intronic/intergenic
rs719593241777857A>C,G,T0.14intergenic_variantHNRNPA1P57 - LDHAP35e-06Tier 4: intronic/intergenic
rs19510821426790837T>A,C,G0.43intron_variantNOVA1-DT, LINC022945e-06Tier 4: intronic/intergenic
rs155748811126749295T>A,C,G0.18intron_variantKIRREL35e-06Tier 4: intronic/intergenic
rs9318128100907093C>G,T0.26intergenic_variantMetazoa_SRP - YWHAZ5e-06Tier 4: intronic/intergenic
rs102296037112988318T>C0.31intron_variantHRAT175e-06Tier 4: intronic/intergenic
rs9990174310998753G>T0.33intron_variantSLC6A16e-06Tier 4: intronic/intergenic

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 27 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
RIT1Orphanet:648Noonan syndrome
SLC6A1Orphanet:178469Autosomal dominant non-syndromic intellectual disability
SLC6A1Orphanet:1942Epilepsy with myoclonic-atonic seizures
YWHAZOrphanet:178469Autosomal dominant non-syndromic intellectual disability
ZBTB16Orphanet:520Acute promyelocytic leukemia
ZBTB16Orphanet:99861Precursor T-cell acute lymphoblastic leukemia
AMOTL1Orphanet:660021Orofacial clefting-cardiac anomalies-facial dysmorphism syndrome
PDHXOrphanet:255182Pyruvate dehydrogenase E3-binding protein deficiency
KIRREL3Orphanet:178469Autosomal dominant non-syndromic intellectual disability
PPM1KOrphanet:268162Intermediate maple syrup urine disease
DHODHOrphanet:246Postaxial acrofacial dysostosis
CC2D2AOrphanet:1454Joubert syndrome with hepatic defect
CC2D2AOrphanet:2318Joubert syndrome with oculorenal defect
CC2D2AOrphanet:564Meckel syndrome
CC2D2AOrphanet:791Retinitis pigmentosa
ERCC4Orphanet:220295Xeroderma pigmentosum-Cockayne syndrome complex
ERCC4Orphanet:84Fanconi anemia
ERCC4Orphanet:90321Cockayne syndrome type 1
ERCC4Orphanet:910Xeroderma pigmentosum
ATP8B1Orphanet:69665Intrahepatic cholestasis of pregnancy
ATP8B1Orphanet:79306Progressive familial intrahepatic cholestasis type 1
ATP8B1Orphanet:99960Benign recurrent intrahepatic cholestasis type 1
LIG4Orphanet:235Dubowitz syndrome
LIG4Orphanet:39041Omenn syndrome
LIG4Orphanet:99812LIG4 syndrome
PDE10AOrphanet:494526Infantile-onset generalized dyskinesia with orofacial involvement
PDE10AOrphanet:494541Childhood-onset benign chorea with striatal involvement

Cohort genes → proteins

45 cohort genes, 45 distinct canonical proteins.

Evidence partition

SubsetGenes
gwas_only45

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
RIT1HGNC:10023ENSG00000143622Q92963GTP-binding protein Rit1gwas
SCN7AHGNC:10594ENSG00000136546Q01118Sodium channel protein type 7 subunit alphagwas
SELPLGHGNC:10722ENSG00000110876Q14242P-selectin glycoprotein ligand 1gwas
SLC6A1HGNC:11042ENSG00000157103P30531Sodium- and chloride-dependent GABA transporter 1gwas
YWHAZHGNC:12855ENSG00000164924P6310414-3-3 protein zeta/deltagwas
ZBTB16HGNC:12930ENSG00000109906Q05516Zinc finger and BTB domain-containing protein 16gwas
C1QTNF7HGNC:14342ENSG00000163145Q9BXJ2Complement C1q tumor necrosis factor-related protein 7gwas
NOAZFPHGNC:15462ENSG00000109445Q9Y3S2Zinc finger protein 330gwas
TOX2HGNC:16095ENSG00000124191Q96NM4TOX high mobility group box family member 2gwas
COLGALT2HGNC:16790ENSG00000198756Q8IYK4Procollagen galactosyltransferase 2gwas
MFHAS1HGNC:16982ENSG00000147324Q9Y4C4Malignant fibrous histiocytoma-amplified sequence 1gwas
PITRM1HGNC:17663ENSG00000107959Q5JRX3Presequence protease, mitochondrialgwas
AMOTL1HGNC:17811ENSG00000166025Q8IY63Angiomotin-like protein 1gwas
RBFOX1HGNC:18222ENSG00000078328Q9NWB1RNA binding protein fox-1 homolog 1gwas
ABHD13HGNC:20293ENSG00000139826Q7L211Protein ABHD13gwas
GSX1HGNC:20374ENSG00000169840Q9H4S2GS homeobox 1gwas
C5orf15HGNC:20656ENSG00000113583Q8NC54Keratinocyte-associated transmembrane protein 2gwas
PDHXHGNC:21350ENSG00000110435O00330Pyruvate dehydrogenase protein X component, mitochondrialgwas
PKD1L2HGNC:21715ENSG00000166473Q7Z442Polycystin-1-like protein 2gwas
PKD1L3HGNC:21716ENSG00000277481Q7Z443Polycystin-1-like protein 3gwas
SPATS1HGNC:22957ENSG00000249481Q496A3Spermatogenesis-associated serine-rich protein 1gwas
KIRREL3HGNC:23204ENSG00000149571Q8IZU9Kin of IRRE-like protein 3gwas
ADH1CHGNC:251ENSG00000248144P00326Alcohol dehydrogenase 1Cgwas
PPM1KHGNC:25415ENSG00000163644Q8N3J5Protein phosphatase Mn(2+)-dependent 1Kgwas
KDM4DHGNC:25498ENSG00000186280Q6B0I6Lysine-specific demethylase 4Dgwas
MYRFLHGNC:26316ENSG00000166268Q96LU7Myelin regulatory factor-like proteingwas
SAMTORHGNC:26475ENSG00000164603Q1RMZ1S-adenosylmethionine sensor upstream of mTORC1gwas
C16orf46HGNC:26525ENSG00000166455Q6P387Uncharacterized protein C16orf46gwas
CWC15HGNC:26939ENSG00000150316Q9P013Spliceosome-associated protein CWC15 homologgwas
DHODHHGNC:2867ENSG00000102967Q02127Dihydroorotate dehydrogenase (quinone), mitochondrialgwas
IST1HGNC:28977ENSG00000182149P53990IST1 homologgwas
CC2D2AHGNC:29253ENSG00000048342Q9P2K1Coiled-coil and C2 domain-containing protein 2Agwas
RGL1HGNC:30281ENSG00000143344Q9NZL6Ral guanine nucleotide dissociation stimulator-like 1gwas
ARHGAP22HGNC:30320ENSG00000128805Q7Z5H3Rho GTPase-activating protein 22gwas
ETV3LHGNC:33834ENSG00000253831Q6ZN32ETS translocation variant 3-like proteingwas
ERCC4HGNC:3436ENSG00000175595Q92889DNA repair endonuclease XPFgwas
ETV3HGNC:3492ENSG00000117036P41162ETS translocation variant 3gwas
ATP8B1HGNC:3706ENSG00000081923O43520Phospholipid-transporting ATPase ICgwas
FZD7HGNC:4045ENSG00000155760O75084Frizzled-7gwas
GPR85HGNC:4536ENSG00000164604P60893Probable G-protein coupled receptor 85gwas
HACL2HGNC:6041ENSG00000105135A1L0T02-hydroxyacyl-CoA lyase 2gwas
LIG4HGNC:6601ENSG00000174405P49917DNA ligase 4gwas
PAWRHGNC:8614ENSG00000177425Q96IZ0PRKC apoptosis WT1 regulator proteingwas
PDE10AHGNC:8772ENSG00000112541Q9Y233cAMP and cAMP-inhibited cGMP 3’,5’-cyclic phosphodiesterase 10Agwas
PTPRDHGNC:9668ENSG00000153707P23468Receptor-type tyrosine-protein phosphatase deltagwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
RIT1GTP-binding protein Rit1Plays a crucial role in coupling NGF stimulation to the activation of both EPHB2 and MAPK14 signaling pathways and in NGF-dependent neuronal differentiation.
SCN7ASodium channel protein type 7 subunit alphaSodium leak channel functioning as an osmosensor regulating sodium ion levels in various tissues and organs.
SELPLGP-selectin glycoprotein ligand 1A SLe(x)-type proteoglycan, which through high affinity, calcium-dependent interactions with E-, P- and L-selectins, mediates rapid rolling of leukocytes over vascular surfaces during the initial steps in inflammation.
SLC6A1Sodium- and chloride-dependent GABA transporter 1Mediates transport of gamma-aminobutyric acid (GABA) together with sodium and chloride and is responsible for the reuptake of GABA from the synapse.
YWHAZ14-3-3 protein zeta/deltaAdapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways.
ZBTB16Zinc finger and BTB domain-containing protein 16Acts as a transcriptional repressor.
TOX2TOX high mobility group box family member 2Putative transcriptional activator involved in the hypothalamo-pituitary-gonadal system.
COLGALT2Procollagen galactosyltransferase 2Beta-galactosyltransferase that transfers beta-galactose to hydroxylysine residues of collagen.
MFHAS1Malignant fibrous histiocytoma-amplified sequence 1Probable GTP-binding protein.
PITRM1Presequence protease, mitochondrialMetalloendopeptidase of the mitochondrial matrix that functions in peptide cleavage and degradation rather than in protein processing.
AMOTL1Angiomotin-like protein 1Inhibits the Wnt/beta-catenin signaling pathway, probably by recruiting CTNNB1 to recycling endosomes and hence preventing its translocation to the nucleus.
RBFOX1RNA binding protein fox-1 homolog 1RNA-binding protein that regulates alternative splicing events by binding to 5’-UGCAUGU-3’ elements.
GSX1GS homeobox 1Probable transcription factor that binds to the DNA sequence 5’-GC[TA][AC]ATTA[GA]-3'.
PDHXPyruvate dehydrogenase protein X component, mitochondrialRequired for anchoring dihydrolipoamide dehydrogenase (E3) to the dihydrolipoamide transacetylase (E2) core of the pyruvate dehydrogenase complexes of eukaryotes.
PKD1L2Polycystin-1-like protein 2May function as a G-protein-coupled receptor.
PKD1L3Polycystin-1-like protein 3Pore-forming subunit of a heterotetrameric, non-selective cation channel that is permeable to Ca(2+).
KIRREL3Kin of IRRE-like protein 3Synaptic adhesion molecule required for the formation of target-specific synapses.
ADH1CAlcohol dehydrogenase 1CAlcohol dehydrogenase.
PPM1KProtein phosphatase Mn(2+)-dependent 1KSerine/threonine-protein phosphatase component of macronutrients metabolism.
KDM4DLysine-specific demethylase 4DHistone demethylase that specifically demethylates ‘Lys-9’ of histone H3, thereby playing a central role in histone code.
SAMTORS-adenosylmethionine sensor upstream of mTORC1S-adenosyl-L-methionine-binding protein that acts as an inhibitor of mTORC1 signaling via interaction with the GATOR1 and KICSTOR complexes.
CWC15Spliceosome-associated protein CWC15 homologInvolved in pre-mRNA splicing as component of the spliceosome.
DHODHDihydroorotate dehydrogenase (quinone), mitochondrialCatalyzes the conversion of dihydroorotate to orotate with quinone as electron acceptor.
IST1IST1 homologESCRT-III-like protein involved in cytokinesis, nuclear envelope reassembly and endosomal tubulation.
CC2D2ACoiled-coil and C2 domain-containing protein 2AComponent of the tectonic-like complex, a complex localized at the transition zone of primary cilia and acting as a barrier that prevents diffusion of transmembrane proteins between the cilia and plasma membranes.
RGL1Ral guanine nucleotide dissociation stimulator-like 1Probable guanine nucleotide exchange factor.
ARHGAP22Rho GTPase-activating protein 22Rho GTPase-activating protein involved in the signal transduction pathway that regulates endothelial cell capillary tube formation during angiogenesis.
ETV3LETS translocation variant 3-like proteinTranscriptional regulator.
ERCC4DNA repair endonuclease XPFCatalytic component of a structure-specific DNA repair endonuclease responsible for the 5-prime incision during DNA repair, and which is essential for nucleotide excision repair (NER) and interstrand cross-link (ICL) repair.
ETV3ETS translocation variant 3Transcriptional repressor that contribute to growth arrest during terminal macrophage differentiation by repressing target genes involved in Ras-dependent proliferation.
ATP8B1Phospholipid-transporting ATPase ICCatalytic component of a P4-ATPase flippase complex which catalyzes the hydrolysis of ATP coupled to the transport of phospholipids, in particular phosphatidylcholines (PC), from the outer to the inner leaflet of the plasma membrane.
FZD7Frizzled-7Receptor for Wnt proteins.
GPR85Probable G-protein coupled receptor 85Orphan receptor.
HACL22-hydroxyacyl-CoA lyase 2Endoplasmic reticulum 2-OH acyl-CoA lyase involved in the cleavage (C1 removal) reaction in the fatty acid alpha-oxydation in a thiamine pyrophosphate (TPP)-dependent manner.
LIG4DNA ligase 4DNA ligase involved in DNA non-homologous end joining (NHEJ); required for double-strand break (DSB) repair and V(D)J recombination.
PAWRPRKC apoptosis WT1 regulator proteinPro-apoptotic protein capable of selectively inducing apoptosis in cancer cells, sensitizing the cells to diverse apoptotic stimuli and causing regression of tumors in animal models.
PDE10AcAMP and cAMP-inhibited cGMP 3’,5’-cyclic phosphodiesterase 10APlays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides.
PTPRDReceptor-type tyrosine-protein phosphatase deltaCan bidirectionally induce pre- and post-synaptic differentiation of neurons by mediating interaction with IL1RAP and IL1RAPL1 trans-synaptically.

Protein-family classification

Druggable: 14 · Difficult: 6 · Unknown: 25 · Druggable fraction: 0.31

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Phosphatase23.7×0.761
Enzyme (other)61.6×0.761
Ion channel12.5×0.785
Protease21.6×0.785
GPCR21.1×0.835
Other/Unknown251.0×0.835
Transcription factor50.9×0.835
Antibody/Immunoglobulin10.7×0.891
Scaffold/PPI10.4×0.932

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
RIT1Other/UnknownnoSmall_GTPase, Small_GTP-bd, Small_GTPase_Ras-type
SCN7AIon channelyesNa_channel_asu, Ion_trans_dom, Na_trans_assoc_dom
SELPLGOther/UnknownnoPSGL-1
SLC6A1Other/UnknownnoNa/ntran_symport, Na/ntran_symport_GABA_GAT1, SNS_sf
YWHAZOther/Unknownno14-3-3, 14-3-3_CS, 14-3-3_domain
ZBTB16Transcription factornoBTB/POZ_dom, SKP1/BTB/POZ_sf, Znf_C2H2_type
C1QTNF7Other/UnknownnoC1q_dom, Collagen, Tumour_necrosis_fac-like_dom
NOAZFPOther/UnknownnoNOA36
TOX2Other/UnknownnoHMG_box_dom, HMG_box_dom_sf, TOX_HMG-box_domain
COLGALT2Enzyme (other)yes2.4.1.50Glyco_trans_25, Nucleotide-diphossugar_trans, Collagen_mod_GT25
MFHAS1Other/UnknownnoLeu-rich_rpt, Leu-rich_rpt_typical-subtyp, ROC
PITRM1Proteaseyes3.4.24.56Peptidase_M16_C, Metalloenz_LuxS/M16, Pept_M16_N
AMOTL1Other/UnknownnoAngiomotin, Angiomotin_C, Angiomotin-like
RBFOX1Other/UnknownnoRRM_dom, Nucleotide-bd_a/b_plait_sf, RBFOX1-3
ABHD13Other/UnknownnoAB_hydrolase_1, AB_hydrolase_fold
GSX1Transcription factornoHD, Homeodomain-like_sf, Homeobox_CS
C5orf15Other/UnknownnoKCT2
PDHXEnzyme (other)yes1.2.1.104Biotin_lipoyl, 2-oxoacid_DH_actylTfrase, 2-oxoA_DH_lipoyl-BS
PKD1L2Other/UnknownnoGPS, Lectin_gal-bd_dom, PLAT/LH2_dom
PKD1L3Other/UnknownnoGPS, PC1, PLAT/LH2_dom
SPATS1Other/UnknownnoSASRP1
KIRREL3Antibody/ImmunoglobulinyesIg_sub2, Ig_sub, Ig-like_dom
ADH1CEnzyme (other)yes1.1.1.1ADH_Zn_CS, GroES-like_sf, ADH-like_C
PPM1KPhosphataseyes3.1.3.16PP2C_BS, PPM-type_phosphatase-like_dom, PP2C
KDM4DEnzyme (other)yes1.14.11.27JmjC_dom, JmjN
MYRFLTranscription factornop53-like_TF_DNA-bd_sf, NDT80_DNA-bd_dom, MYRF_C2
SAMTOROther/UnknownnoBmt2/SAMTOR, SAM-dependent_MTases_sf
C16orf46Other/UnknownnoDUF4529
CWC15Other/UnknownnoCwf_Cwc_15
DHODHEnzyme (other)yes1.3.5.2Dihydroorotate_DH_CS, Dihydroorotate_DH_2, Dihydroorotate_DH_cat
IST1Other/UnknownnoIst1, IST1-like
CC2D2AProteaseyesC2_dom, CC2D2AN-C2, C2_domain_sf
RGL1Other/UnknownnoRA_dom, Ras-like_Gua-exchang_fac_N, RASGEF_cat_dom
ARHGAP22Scaffold/PPInoRhoGAP_dom, PH_domain, Rho_GTPase_activation_prot
ETV3LOther/UnknownnoEts_dom, WH-like_DNA-bd_sf, WH_DNA-bd_sf
ERCC4Other/UnknownnoERCC4_domain, XPF, RuvA_2-like
ETV3Other/UnknownnoEts_dom, WH-like_DNA-bd_sf, WH_DNA-bd_sf
ATP8B1Transcription factorno7.6.2.1P_typ_ATPase, P-type_ATPase_IV, ATPase_P-typ_transduc_dom_A_sf
FZD7GPCRyesFrizzled/Smoothened_7TM, Frizzled/SFRP, GPCR_2-like_7TM
GPR85GPCRyesGPCR_Rhodpsn, GPCR_Rhodpsn_7TM, GPCR_Orphan/Phoenixin
HACL2Other/UnknownnoTPP-bd_CS, TPP_enzyme_TPP-bd, Thiamin_PyroP_enz_cen_dom
LIG4Enzyme (other)yes6.5.1.1DNA_ligase_ATP-dep, BRCT_dom, DNA_ligase_ATP-dep_N
PAWROther/UnknownnoPar-4
PDE10ATranscription factorno3.1.4.17PDEase_catalytic_dom, GAF, HD/PDEase_dom
PTPRDPhosphataseyes3.1.3.48PTP_cat, Tyr_Pase_dom, Tyr_Pase_cat

Expression context

Cohort genes with no expression data: 0.

39 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)1
broad (>20)44
unknown0

Top tissues across cohort

TissueCohort genes
cortical plate5
secondary oocyte5
Brodmann (1909) area 234
germinal epithelium of ovary4
leukocyte3
tibialis anterior3
oocyte3
adrenal tissue3
apex of heart3
cardiac muscle of right atrium3
male germ line stem cell (sensu Vertebrata) in testis3
primordial germ cell in gonad3
endothelial cell3
monocyte2
cerebellar vermis2
skin of hip2
calcaneal tendon2
mucosa of stomach2
thymus2
C1 segment of cervical spinal cord2

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
RIT1268ubiquitousmarkermonocyte, mononuclear cell, leukocyte
SCN7A226broadmarkertrigeminal ganglion, sural nerve, right lung
SELPLG255broadmarkergranulocyte, blood, leukocyte
SLC6A1207broadmarkerlateral nuclear group of thalamus, lateral globus pallidus, cerebellar vermis
YWHAZ295ubiquitousmarkergingival epithelium, cortical plate, tongue squamous epithelium
ZBTB16281broadmarkerskin of hip, Brodmann (1909) area 23, tibialis anterior
C1QTNF7192broadmarkercalcaneal tendon, popliteal artery, tibial artery
NOAZFP297ubiquitousmarkersecondary oocyte, germinal epithelium of ovary, oocyte
TOX2196ubiquitousmarkersecondary oocyte, thymus, mucosa of stomach
COLGALT2242broadmarkertibia, corpus callosum, C1 segment of cervical spinal cord
MFHAS1266ubiquitousmarkersaphenous vein, secondary oocyte, renal medulla
PITRM1292ubiquitousmarkerapex of heart, adrenal tissue, right adrenal gland cortex
AMOTL1251ubiquitousmarkertibialis anterior, deltoid, cardiac muscle of right atrium
RBFOX1220broadmarkermiddle temporal gyrus, Brodmann (1909) area 23, cortical plate
ABHD13214ubiquitousmarkermonocyte, leukocyte, calcaneal tendon
GSX118tissue_specificyessuperficial temporal artery, buccal mucosa cell, epithelium of nasopharynx
C5orf15303ubiquitousmarkertibia, bronchial epithelial cell, germinal epithelium of ovary
PDHX296ubiquitousmarkerbiceps brachii, heart right ventricle, skeletal muscle tissue of biceps brachii
PKD1L2156broadmarkerseminal vesicle, apex of heart, subcutaneous adipose tissue
PKD1L342tissue_specificmarkermale germ line stem cell (sensu Vertebrata) in testis, right lobe of liver, liver
SPATS163tissue_specificyesright uterine tube, primordial germ cell in gonad, left testis
KIRREL3179broadmarkermiddle temporal gyrus, nucleus accumbens, Brodmann (1909) area 23
ADH1C199tissue_specificmarkermucosa of transverse colon, jejunal mucosa, nasal cavity epithelium
PPM1K259ubiquitousmarkerleft ventricle myocardium, cardiac muscle of right atrium, myocardium
KDM4D161broadyesbuccal mucosa cell, left testis, testis
MYRFL148tissue_specificmarkerprimordial germ cell in gonad, jejunal mucosa, duodenum
SAMTOR240ubiquitousyessecondary oocyte, cortical plate, oocyte
C16orf46129ubiquitousmarkermale germ line stem cell (sensu Vertebrata) in testis, primordial germ cell in gonad, testis
CWC15262ubiquitousmarkerkidney epithelium, tibialis anterior, cardiac muscle of right atrium
DHODH179ubiquitousmarkerright lobe of liver, liver, right atrium auricular region

Protein interactions among cohort

Intra-cohort edges: 7.

Hub genes (top 10 by interactor count)

SymbolInteractor count
YWHAZ3,588
PDHX3,542
ZBTB163,514
RIT13,298
DHODH3,148
PTPRD3,052
RBFOX12,990
SLC6A12,841
SELPLG2,655
HACL22,599

Intra-cohort edges

ABSources
AMOTL1YWHAZintact
ARHGAP22NOAZFPstring_interaction
HACL2MYRFLstring_interaction
MFHAS1TOX2biogrid_interaction, intact
MYRFLPKD1L3string_interaction
PITRM1PPM1Kbiogrid_interaction
RGL1RIT1intact

Structural data

PDB: 25 · AlphaFold-only: 20 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
PDE10AQ9Y233359
KDM4DQ6B0I6284
DHODHQ02127105
YWHAZP6310477
CWC15Q9P01334
LIG4P4991731
IST1P5399016
ERCC4Q9288913
ATP8B1O4352013
FZD7O7508413
PITRM1Q5JRX38
PTPRDP234688
SLC6A1P305315
PDHXO003305
RBFOX1Q9NWB14
RIT1Q929633
ZBTB16Q055163
PPM1KQ8N3J53
SCN7AQ011182
ADH1CP003262
RGL1Q9NZL62
SELPLGQ142421
KIRREL3Q8IZU91
SAMTORQ1RMZ11
PAWRQ96IZ01

AlphaFold-only cohort genes (top 30 by pLDDT)

SymbolUniProtpLDDT
HACL2A1L0T094.53
ABHD13Q7L21192.06
COLGALT2Q8IYK488.44
MFHAS1Q9Y4C484.62
GPR85P6089382.93
NOAZFPQ9Y3S276.52
C1QTNF7Q9BXJ274.35
PKD1L2Q7Z44271.44
ARHGAP22Q7Z5H370.00
CC2D2AQ9P2K169.46
MYRFLQ96LU768.13
GSX1Q9H4S265.45
PKD1L3Q7Z44365.18
AMOTL1Q8IY6361.14
SPATS1Q496A358.12
C5orf15Q8NC5457.94
ETV3LQ6ZN3256.93
ETV3P4116256.10
TOX2Q96NM451.70
C16orf46Q6P38750.10

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 137. Enrichment computed across 45 evidence-associated genes (28 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 28 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Pyrimidine biosynthesis1135.9×0.253DHODH
Reuptake of GABA1102.0×0.253SLC6A1
Signalling to p38 via RIT and RIN181.6×0.253RIT1
MECP2 regulates transcription factors181.6×0.253RBFOX1
H139Hfs13* PPM1K causes a mild variant of MSUD181.6×0.253PPM1K
2-LTR circle formation158.3×0.253LIG4
PDH complex synthesizes acetyl-CoA from PYR158.3×0.253PDHX
NOTCH4 Activation and Transmission of Signal to the Nucleus137.1×0.253YWHAZ
GP1b-IX-V activation signalling134.0×0.253YWHAZ
Ethanol oxidation134.0×0.253ADH1C
Regulation of localization of FOXO transcription factors134.0×0.253YWHAZ
WNT5:FZD7-mediated leishmania damping134.0×0.253FZD7
SARS-CoV-2 targets host intracellular signalling and regulatory pathways131.4×0.253YWHAZ
Signaling by Retinoic Acid229.1×0.253PDHX, ADH1C
Activation of BAD and translocation to mitochondria127.2×0.253YWHAZ
Regulation of mRNA stability by proteins that bind AU-rich elements127.2×0.253YWHAZ
Regulation of pyruvate dehydrogenase (PDH) complex125.5×0.253PDHX
Rap1 signalling125.5×0.253YWHAZ
cGMP effects125.5×0.253PDE10A
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex124.0×0.253YWHAZ
SARS-CoV-1 targets host intracellular signalling and regulatory pathways124.0×0.253YWHAZ
KSRP (KHSRP) binds and destabilizes mRNA122.7×0.253YWHAZ
GABA synthesis, release, reuptake and degradation122.7×0.253SLC6A1
Receptor-type tyrosine-protein phosphatases120.4×0.253PTPRD
Signaling by Hippo119.4×0.253AMOTL1
Synaptic adhesion-like molecules119.4×0.253PTPRD
Activation of BH3-only proteins117.7×0.253YWHAZ
Signaling by NOTCH4117.7×0.253YWHAZ
Nephrin family interactions117.0×0.253KIRREL3
RA biosynthesis pathway117.0×0.253ADH1C

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 39 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
obsolete isoleucine biosynthetic process1432.1×0.069HACL2
negative regulation of ectodermal cell fate specification1432.1×0.069FZD7
establishment of integrated proviral latency1432.1×0.069LIG4
regulation of plasma membrane organization1432.1×0.069ATP8B1
detection of chemical stimulus involved in sensory perception of sour taste1216.1×0.069PKD1L3
inter-male aggressive behavior1216.1×0.069KIRREL3
synaptic target recognition1216.1×0.069YWHAZ
leukocyte adhesive activation1216.1×0.069SELPLG
inorganic anion import across plasma membrane1216.1×0.069SLC6A1
positive regulation of chromosome organization1216.1×0.069LIG4
establishment of cell polarity involved in ameboidal cell migration1144.0×0.069AMOTL1
pyrimidine ribonucleotide biosynthetic process1144.0×0.069DHODH
principal sensory nucleus of trigeminal nerve development1144.0×0.069KIRREL3
‘de novo’ UMP biosynthetic process1144.0×0.069DHODH
male germ-line stem cell asymmetric division1144.0×0.069ZBTB16
glomerulus morphogenesis1144.0×0.069KIRREL3
trans-synaptic signaling by trans-synaptic complex1144.0×0.069PTPRD
nucleotide-excision repair involved in interstrand cross-link repair1144.0×0.069ERCC4
pro-B cell differentiation1108.0×0.069LIG4
tolerance induction in gut-associated lymphoid tissue1108.0×0.069ZBTB16
L-valine biosynthetic process1108.0×0.069HACL2
T cell receptor V(D)J recombination1108.0×0.069LIG4
positive regulation of NK T cell differentiation1108.0×0.069ZBTB16
gamma-aminobutyric acid reuptake1108.0×0.069SLC6A1
telomeric DNA-containing double minutes formation1108.0×0.069ERCC4
positive regulation of hydrogen peroxide-mediated programmed cell death1108.0×0.069PAWR
DN2 thymocyte differentiation1108.0×0.069LIG4
negative regulation of protection from non-homologous end joining at telomere1108.0×0.069ERCC4
regulation of chloride transport1108.0×0.069ATP8B1
detection of mechanical stimulus261.7×0.069PKD1L2, PKD1L3

Therapeutics

Drugs indicated for this disease

2 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugDevelopment status
ChlorpromazineApproved (phase 4)
HaloperidolApproved (phase 4)
Lithium CarbonatePhase 3 (in late-stage trials)
RisperidonePhase 3 (in late-stage trials)

Drug target analysis

Approved (phase 4): 4 · Phase ≥3: 5 · Phased (≥1): 7 · Undrugged: 38

Druggability breadth: 18 of 45 evidence-associated genes (40%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

SymbolExample approved molecule
SCN7AIMIPRAMINE
SLC6A1TIAGABINE
DHODHATOVAQUONE
PDE10AVARDENAFIL

Top cohort targets by molecule count

SymbolMoleculesMax phase
SCN7A204
PDE10A164
DHODH134
SLC6A134
SELPLG12
PITRM113
KDM4D12
RIT100
YWHAZ00
ZBTB1600

Drugs targeting cohort genes (top 30)

MoleculeMax phaseTargets in cohort
IMIPRAMINE4SCN7A
SERTINDOLE4SCN7A
PIMOZIDE4SCN7A
NIFEDIPINE4SCN7A
DILTIAZEM4SCN7A
MIBEFRADIL4SCN7A
HALOPERIDOL4SCN7A
MEXILETINE4SCN7A
AMITRIPTYLINE4SCN7A
AMIODARONE4SCN7A
CHLORPROMAZINE4SCN7A
TETRACAINE4SCN7A
TIAGABINE4SLC6A1
TIAGABINE HYDROCHLORIDE4SLC6A1
ATOVAQUONE4DHODH
LEFLUNOMIDE4DHODH
TERIFLUNOMIDE4DHODH
VARDENAFIL4PDE10A
SILDENAFIL4PDE10A
CINCHOPHEN4PDE10A
DIPYRIDAMOLE4PDE10A
TEDISAMIL3SCN7A
NITRENDIPINE3SCN7A
AJMALINE3SCN7A
VIXOTRIGINE3SCN7A
TETRODOTOXIN3SCN7A
TALABOSTAT3PITRM1
VIDOFLUDIMUS3DHODH
PAPAVERINE3PDE10A
CIFENLINE2SCN7A

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 11.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

SymbolAssaysType breakdown
PDE10A357Binding:345, ADMET:9, Functional:3
DHODH297Binding:286, ADMET:7, Functional:2, Toxicity:2
SLC6A156Binding:55, Functional:1
SCN7A48Binding:32, Functional:16
KDM4D43Binding:41, Functional:2
ERCC428Binding:28
YWHAZ23Binding:23
PITRM115Binding:15
SELPLG13Binding:13
ADH1C12Binding:12
FZD78Binding:8
ZBTB163Binding:3
GPR852Binding:2
LIG42Binding:2
PDHX1Binding:1
CWC151Binding:1
HACL21Binding:1
PTPRD1Binding:1

Cohort enzymes (BRENDA EC)

SymbolEC numbersNames
COLGALT22.4.1.50procollagen galactosyltransferase
PITRM13.4.24.56insulysin
PDHX1.2.1.104pyruvate dehydrogenase system
ADH1C1.1.1.1alcohol dehydrogenase
PPM1K3.1.3.16, 3.1.3.52protein-serine/threonine phosphatase, [3-methyl-2-oxobutanoate dehydrogenase (2-methylpropanoyl-transferring)]-phosphatase
KDM4D1.14.11.27, 1.14.11.66[histone H3]-dimethyl-L-lysine36 demethylase, [histone H3]-trimethyl-L-lysine9 demethylase
DHODH1.3.5.2dihydroorotate dehydrogenase (quinone)
ATP8B17.6.2.1P-type phospholipid transporter
LIG46.5.1.1DNA ligase (ATP)
PDE10A3.1.4.173’,5’-cyclic-nucleotide phosphodiesterase
PTPRD3.1.3.48protein-tyrosine-phosphatase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

SymbolChEMBL assays
DHODH297
PDE10A357

Pharmacogenomics

Cohort genes with a PharmGKB record: 45; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

30 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

CompoundMax phaseCohort target (bioactivity)
IMIPRAMINE4SCN7A
SERTINDOLE4SCN7A
PIMOZIDE4SCN7A
NIFEDIPINE4SCN7A
DILTIAZEM4SCN7A
MIBEFRADIL4SCN7A
HALOPERIDOL4SCN7A
MEXILETINE4SCN7A
AMITRIPTYLINE4SCN7A
AMIODARONE4SCN7A
CHLORPROMAZINE4SCN7A
TETRACAINE4SCN7A
TIAGABINE4SLC6A1
TIAGABINE HYDROCHLORIDE4SLC6A1
ATOVAQUONE4DHODH
LEFLUNOMIDE4DHODH
TERIFLUNOMIDE4DHODH
VARDENAFIL4PDE10A
SILDENAFIL4PDE10A
CINCHOPHEN4PDE10A
DIPYRIDAMOLE4PDE10A
TEDISAMIL3SCN7A
NITRENDIPINE3SCN7A
AJMALINE3SCN7A
VIXOTRIGINE3SCN7A
TETRODOTOXIN3SCN7A
TALABOSTAT3PITRM1
VIDOFLUDIMUS3DHODH
PAPAVERINE3PDE10A
CIFENLINE2SCN7A

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)4SCN7A, SLC6A1, DHODH, PDE10A
BPhased (≥1) drug, not yet approved3SELPLG, PITRM1, KDM4D
CDruggable family + PDB, no drug7PDHX, KIRREL3, ADH1C, PPM1K, FZD7, LIG4, PTPRD
DDruggable family + AlphaFold only, no drug3COLGALT2, CC2D2A, GPR85
EDifficult family or no structure, no drug28RIT1, YWHAZ, ZBTB16, C1QTNF7, NOAZFP, TOX2, MFHAS1, AMOTL1, RBFOX1, ABHD13 (+18 more)

Undrugged target profiles

38 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
RIT10—
YWHAZ23—
ZBTB163—
C1QTNF70—
NOAZFP0—
TOX20—
COLGALT20—
MFHAS10—
AMOTL10—
RBFOX10—
ABHD130—
GSX10—
C5orf150—
PDHX1—
PKD1L20—
PKD1L30—
SPATS10—
KIRREL30—
ADH1C12—
PPM1K0—
MYRFL0—
SAMTOR0—
C16orf460—
CWC151—
IST10—
CC2D2A0—
RGL10—
ARHGAP220—
ETV3L0—
ERCC428—

Clinical trials & evidence

Clinical trials

Clinical trials: 82.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified57
PHASE46
PHASE35
PHASE25
PHASE14
PHASE1/PHASE23
PHASE2/PHASE32

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00051714PHASE4COMPLETEDEarly Prevention of Conduct Problems
NCT00154362PHASE4COMPLETEDThe Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Adolescents With Impulsivity and Aggressive Behavior in Conduct Disorder This Study is Not Being Conducted in the United States.
NCT00228046PHASE4COMPLETEDMedication Strategies for Treating Aggressive Behavior in Youth With Attention Deficit Hyperactivity Disorder
NCT00250705PHASE4COMPLETEDTrial of Aripiprazole in the Treatment of CD in Adolescents
NCT02063945PHASE4TERMINATEDMethylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders
NCT04170738PHASE4COMPLETEDBrain Indices of Stimulant Treatment in Drug-Naive Youth at Risk for Substance Use Disorder
NCT00000385PHASE3COMPLETEDLong-Term Lithium Treatment for Aggressive Conduct Disorder
NCT00250354PHASE3COMPLETEDA Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation
NCT00266552PHASE3COMPLETEDA Study of the Safety and Effectiveness of Risperidone Versus Placebo for the Treatment of Conduct Disorder in Children With Mild, Moderate, or Borderline Mental Retardation
NCT00344474PHASE2/PHASE3COMPLETEDPersonality-targeted Interventions for Adolescent Alcohol Misuse
NCT00399698PHASE3COMPLETEDStudy to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone.
NCT00776685PHASE2/PHASE3COMPLETEDAdventure: Teacher Delivered Personality-targeted Interventions for Substance Misuse
NCT01594606PHASE3COMPLETEDRandomized Control Trial of an Animal-Assisted Intervention With Adjudicated Youth
NCT06831123PHASE1/PHASE2RECRUITINGPathways 2 Success
NCT00051727PHASE2COMPLETEDPrevention of School Dropout for Mexican American Adolescents
NCT00280228PHASE2COMPLETEDHome Based Treatment for Drug Use in Early Adolescents
NCT00626236PHASE2COMPLETEDPhase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems
NCT00676429PHASE2COMPLETEDZiprasidone for Severe Conduct and Other Disruptive Behavior Disorders
NCT01494831PHASE2COMPLETEDRandomized Control Trial of Group Intervention With Former War-affected Boys in the Democratic Republic of Congo
NCT02093052PHASE1/PHASE2UNKNOWNIntervening Early With Neglected Children
NCT02247986PHASE1/PHASE2WITHDRAWNInvestigating the Impact of Methylphenidate on Neural Response in Disruptive Behavioral Disorder
NCT00149812PHASE1COMPLETEDA Clinic-based Prevention Program for Families of Depressed Mothers
NCT01267773PHASE1UNKNOWNTreatment of Conduct Problems and Depression
NCT03292848PHASE1COMPLETEDTrial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders
NCT06301516PHASE1COMPLETEDImpact VR: An Emotion Recognition and Regulation Training Program for Youth With CD
NCT01653535Not specifiedACTIVE_NOT_RECRUITINGMultisite Prevention of Conduct Problems (Fast Track)
NCT04631042Not specifiedRECRUITINGDeveloping Brain, Impulsivity and Compulsivity
NCT05449002Not specifiedRECRUITINGDigital Single Session Intervention for Youth Mental Health
NCT05606978Not specifiedACTIVE_NOT_RECRUITINGThe Effectiveness of Blended Forensic Ambulant Systemic Therapy
NCT05637320Not specifiedRECRUITINGBig Feelings: A Study on Children’s Emotions in Therapy
NCT05802758Not specifiedRECRUITINGCFT-focused Mental Health Intervention With Exposure Training for Youngsters
NCT06032520Not specifiedRECRUITINGThe Effectiveness of Forensic Outpatient Systemic Therapy: a Multiple Case Experimental Design
NCT06373484Not specifiedRECRUITINGMatching Assessment and Treatment for Children With Disruptive Behaviour and Their Parents
NCT06657430Not specifiedRECRUITINGA Study on the Preference of Risperidone Dosage Forms
NCT07091721Not specifiedRECRUITINGUsing Mentalization Based Therapy to Support Children and Adolescents Referred to Specialist Mental Health Services in the NHS for Aggressive and/or Violent Behaviour
NCT07273695Not specifiedRECRUITINGAssessing Real Life Effectiveness of Treatment in Neurodevelopmental Disorders
NCT07322055Not specifiedACTIVE_NOT_RECRUITINGGenetic and Clinical Correlates of Disruptive Behavior Disorder With and Without Callous-Unemotional Traits
NCT00104039Not specifiedCOMPLETEDBrain Changes in Children and Adolescents With Behavioral Problems
NCT00189189Not specifiedUNKNOWNPrevention of Oppositional Defiant and Conduct Disorders in Preschool Children
NCT00404911Not specifiedCOMPLETEDMulti-Family Group Therapy for Reducing Behavioral Difficulties in Youth

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
METHYLPHENIDATE43
ARIPIPRAZOLE41
BREXPIPRAZOLE41
DEXTROAMPHETAMINE41
DIVALPROEX SODIUM41
LEVAMFETAMINE41
MOLINDONE41
OXCARBAZEPINE41
ZIPRASIDONE HYDROCHLORIDE41
LITHIUM31
LITHIUM ION01

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 71

This page pulls from 71 datasets indexed by BioBTree:

alphafoldantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticscellosauruschembl_activitychembl_assaychembl_documentchembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsclinvarctd_gene_interactiondbsnpdepmapdiamond_similaritydoidefoensemblentrezesm2_similarityfantom5_genefantom5_promotergenccgenerifgogtopdbgtopdb_interactiongwasgwas_studyhgncintactinterpromedgenmeshmimmondomondochildmondoparentncitorphanetpatentpatent_compoundpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assayreactomerefseqrhearnacentralsctidscxa_expressionscxa_gene_experimentsignorstring_interactiontranscriptufeatureumlsuniprot